X4 Pharmaceuticals Cash Conversion Cycle | XFOR

Annual Cash Conversion Cycle X4 Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-318	-3.3 K	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-318	-3.3 K	-1.81 K

Quarterly Cash Conversion Cycle X4 Pharmaceuticals

2026-Q2	2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-1.6 K	-2.59 K	-111	-	-3.33 K	-2.88 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	45.6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
45.6	-3.33 K	-1.74 K

Cash Conversion Cycle of other stocks in the Biotechnology industry

Issuer	Cash Conversion Cycle	Price	% 24h	Market Cap	Country
Zoetis ZTS	317	$ 71.41	2.45 %	$ 31.7 B	USA
Dr. Reddy's Laboratories Limited RDY	230	$ 12.32	0.57 %	$ 10.3 B	India
Mirati Therapeutics MRTX	12.7	-	-	$ 3.3 B	USA
Gritstone Oncology GRTS	40.3	-	0.42 %	$ 213 M	USA
Nymox Pharmaceutical Corporation NYMX	-2.39 K	-	-19.68 %	$ 18.4 M	Canada
HOOKIPA Pharma HOOK	3.33	-	-6.92 %	$ 79.4 M	USA
Guardion Health Sciences GHSI	160	-	-0.31 %	$ 3.64 M	USA
Opiant Pharmaceuticals OPNT	84.9	-	-	$ 109 M	USA
Orchard Therapeutics plc ORTX	-295	-	1.02 %	$ 90.8 M	Britain
La Jolla Pharmaceutical Company LJPC	34.8	-	-	$ 154 M	USA
Oyster Point Pharma OYST	-272	-	-	$ 300 M	USA
Intercept Pharmaceuticals ICPT	-3.11 K	-	-	$ 643 M	USA
9 Meters Biopharma NMTR	27.9	-	-42.97 %	$ 1.05 M	USA
Otonomy OTIC	-844	-	-1.96 %	$ 4.68 M	USA
Chinook Therapeutics KDNY	0.93	-	-	$ 2.6 B	USA
PhaseBio Pharmaceuticals PHAS	191	-	7.4 %	$ 6.29 M	USA
Provention Bio PRVB	19.2	-	-	$ 2.37 B	USA
Poseida Therapeutics PSTX	51	-	-	$ 857 M	USA
PolarityTE PTE	32	-	-0.82 %	$ 1.78 M	USA
Reata Pharmaceuticals RETA	-5.6	-	-	$ 6.29 B	USA
Lumos Pharma LUMO	13.7	-	-	$ 35.3 M	USA
Syros Pharmaceuticals SYRS	0.05	-	-8.44 %	$ 3.4 M	USA
SpringWorks Therapeutics SWTX	-42.3	-	-	$ 3.48 B	USA
Trevena TRVN	-412	-	-46.58 %	$ 31.8 M	USA
Y-mAbs Therapeutics YMAB	82.3	-	-	$ 382 M	USA
Oncternal Therapeutics ONCT	-345	-	-24.12 %	$ 1.56 M	USA
Navidea Biopharmaceuticals NAVB	-279 K	-	-2.99 %	$ 2.47 M	USA
Albireo Pharma ALBO	-1.55 K	-	-0.23 %	$ 916 M	USA
bluebird bio BLUE	72.4	-	-	$ 546 M	USA
Intra-Cellular Therapies ITCI	257	-	-	$ 13.6 B	USA
CASI Pharmaceuticals CASI	126	-	-	$ 35.4 M	USA
ContraFect Corporation CFRX	-1.83 K	-	-5.16 %	$ 5.39 M	USA
Epizyme EPZM	-308	-	-	$ 249 M	USA